Skip to main content

Abstract

Uptake sites rapidly remove catecholamines from the synaptic cleft and terminate neurotransmitter action prior to recycling into storage vesicles ready for further release. These uptake sites are sodium dependent and are probably present over much of the neuron since both uptake and release of dopamine (DA) has been demonstrated in dendrites, at least in the substantia nigra. Mazindol is a potent inhibitor of catecholamine uptake and binds with a high affinity to single binding sites. Affinity for noradrenaline (NA) uptake sites is greatest (IC50 for [3H] amine uptake into synaptosomes 0.65 µM), while affinity for DA uptake sites is also high (IC50 18 µM) (Hyttel 1982). Because of the high affinity of desipramine (DMI) for noradrenergic uptake sites (IC50 0.97), but low affinity for DA uptake sites (IC50 9100) the addition of this compound may be used to distinguish between NA and DA uptake sites when using [3H] Mazindol binding. Since we and others have used [3H] Mazindol binding as a useful technique to study the effects of the neurotoxin 1-methyl-4-phenyl, 1,2,3,6 tetrahydropyridine (MPTP) on DA uptake sites in mouse brain (Donnan et al 1987, Javitch et al 1986), we have documented the regional distribution of binding to DA and NA uptake sites as a basis for further study.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 59.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  • Bjorklund, A., Lindvall, O. (1984). Dopamine-Containing Systems in the CNS. In: Handbook of Chemical Neuroanatomy, 2, 55–111. Elsevier

    Google Scholar 

  • Donnan, G.A., Kaczmarczyk, S.J., McKenzie, J.S., Rowe, P.J., Kalnins, R.M., Mendelsohn, F.A.O. (1987). MPTP Affects Dopaminergic Terminal Fields in Mouse Brain with Complete Recovery in 12 Months. J. Neurol Sci (In Press)

    Google Scholar 

  • Hyttel, J. (1982). Citalopram — Pharmacological Profile of a Specific Serotonin Uptake Inhibitor with Antidepressant Activity. Prog. Neuropsychopharmacol. Biol. Psychiatry 6, 277–295

    CAS  Google Scholar 

  • Javitch, J.A., D’Amato, R.J., Strittmatter, S.M., Snyder, S.H. (1986). Parkinsonism-Inducing Neurotoxin, N-methyl-4-phenyl — 1,2,3,6 tetrahydropyridine: Uptake of the N-4-phenylpyridine by Dopamine Neurones Explains Selective Toxicity. Proc. Natl. Acad Sci. U.S.A. 82, 2173–2177

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Editor information

Editors and Affiliations

Copyright information

© 1988 Geoffrey A. Donnan, Stan S. Kaczmarczyk, John S. McKenzie, Renate M. Kalnins and Frederick A.O. Mendelsohn

About this chapter

Cite this chapter

Donnan, G.A., Kaczmarczyk, S.S., McKenzie, J.S., Kalnins, R.M., Mendelsohn, F.A.O. (1988). The Distribution of Catecholamine Uptake Sites in Mouse Brain. In: Beart, P.M., Woodruff, G.N., Jackson, D.M. (eds) Pharmacology and Functional Regulation of Dopaminergic Neurons. Satellite Symposia of the IUPHAR 10th International Congress of Pharmacology. Palgrave Macmillan, London. https://doi.org/10.1007/978-1-349-10047-7_43

Download citation

Publish with us

Policies and ethics